Medication use in a large international sample of people with multiple sclerosis: Associations with quality of life, relapse rate and disability

Neurological Research

Volumn 37, Issue 8, 2015, Pages 662-673

  Jelinek, George A ^a,b,c   Weiland, Tracey J ^a,c   Hadgkiss, Emily J ^a   Marck, Claudia H ^a   Pereira, Naresh ^d   Van Der Meer, Dania M ^a  

^a ST VINCENT S HOSPITAL   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d BOX HILL HOSPITAL   (Australia)

Author keywords

Disability; Disease modifying drugs; Health related quality of life; Medications; Multiple sclerosis; Relapse rate

Indexed keywords

FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; INTERFERON; NALTREXONE; NATALIZUMAB; NON PRESCRIPTION DRUG; TERIFLUNOMIDE; IMMUNOLOGIC FACTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISABILITY; EXPANDED DISABILITY STATUS SCALE; FATIGUE SEVERITY SCALE; FEMALE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MENTAL HEALTH; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; POLYPHARMACY; QUALITY OF LIFE; RECURRENCE RISK; SHORT FORM 36; COHORT ANALYSIS; INTERNATIONAL COOPERATION; INTERNET; MIDDLE AGED; PATHOPHYSIOLOGY; PSYCHOLOGY; RECURRENT DISEASE; SELF REPORT; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; COHORT STUDIES; DISABILITY EVALUATION; FEMALE; GLATIRAMER ACETATE; HUMANS; IMMUNOLOGIC FACTORS; INTERFERONS; INTERNATIONALITY; INTERNET; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; POLYPHARMACY; QUALITY OF LIFE; RECURRENCE; SELF REPORT; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84933521062     PISSN: 01616412     EISSN: 17431328     Source Type: Journal    
DOI: 10.1179/1743132815Y.0000000036     Document Type: Article

References (37)

1. Wingerchuk DM, Carter JL. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Mayo Clin Proc. 2014;89:225–40
2. Khan O, Rieckmann P, Boyko A, Selmaj K, Zivadinov R, GALA Study Group. Three times weekly glatiramer acetate in relapsingremitting multiple sclerosis. Ann Neurol. 2013;73:705–13
3. Dörr J, Bitsch A, Schmailzl KJ, Chan A, von Ahsen N, Hummel M, et al. Severe cardiac failure in a patient with multiple sclerosis following low-dose mitoxantrone treatment. Neurol. 2009;73:991–3
4. Martinelli Boneschi F, Vacchi L, Rovaris M, Capra R, Comi G. Mitoxantrone for multiple sclerosis. Cochrane Database Syst Rev. 2013;5:CD002127
5. Cree BA. 2014 multiple sclerosis therapeutic update. Neurohospitalist. 2014;4:63–5
6. Raftery JP. Paying for costly pharmaceuticals: regulation of new drugs in Australia, England and New Zealand. Med J Aust. 2008;188:26–8
7. Hadgkiss EJ, Jelinek GA, Weiland TJ, Pereira NG, Marck CH, van der Meer DM. Methodology of an international study of people with multiple sclerosis recruited through web 2.0 platforms: demographics, lifestyle, and disease characteristics. Neurol Res Int. 2013;2013:580596
8. Solari A, Filippini G, Mendozzi L, Ghezzi A, Cifani S, Barbieri E, et al. Validation of Italianmultiple sclerosis quality of life 54 questionnaire. J Neurol Neurosurg Psychiatry. 1999;67:158–62
9. Yamamoto T, Ogata K, Katagishi M, Shimizu H, Ogawa M, Yamamura T, et al. [Validation of the Japanese-translated version multiple sclerosis quality of life-54 instrument]. Rinsho Shinkeigaku. 2004;44:417–21
10. Acquadro C, Lafortune L, Mear I. Quality of life in multiple sclerosis: translation in French Canadian of the MSQoL-54. Health Qual Life Outcomes. 2003;1:70
11. Amato MP, Ponziani G, Rossi F, Liedl CL, Stefanile C, Rossi L. Quality of life in multiple sclerosis: the impact of depression, fatigue and disability. Mult Scler. 2001;7:340–4
12. Wang JL, Reimer MA, Metz LM, Patten SB. Major depression and quality of life in individuals with multiple sclerosis. Int J Psychiatry Med. 2000;30:309–17
13. Tepavcevic DK, Kostic J, Basuroski ID, Stojsavljevic N, Pekmezovic T, Drulovic J. The impact of sexual dysfunction on the quality of life measured by MSQoL-54 in patients with multiple sclerosis. Mult Scler. 2008;14:1131–6
14. Hohol MJ, Orav EJ, Weiner HL. Disease steps in multiple sclerosis: a simple approach to evaluate disease progression. Neurology. 1995;45:251–5
15. Hohol MJ, Orav EJ, Weiner HL. Disease steps in multiple sclerosis: a longitudinal study comparing disease steps and EDSS to evaluate disease progression. Mult Scler. 1999;5:349
16. Marrie RA, Cutter G, Tyry T, Hadjimichael O, Campagnolo D, Vollmer T. Changes in the ascertainment of multiple sclerosis. Neurology. 2005;65:1066–70
17. Marrie RA, Cutter G, Tyry T, Vollmer T, Campagnolo D. Does multiple sclerosis-associated disability differ between races? Neurology. 2006;66:1235–40
18. Hadjimichael O, Vollmer T, Oleen-Burkey M. North American Research Committee on Multiple Sclerosis. Fatigue characteristics in multiple sclerosis: the North American Research Committee on Multiple Sclerosis (NARCOMS) survey. Health Qual Life Outcomes. 2008;6:100
19. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46:1121–3
20. World Health Organization. Available from: http://www.who.int/mediacentre/factsheets/fs311/en/ (accessed 2014 July 3) Obesity and overweight. Geneva: World Health Organization; 2014
21. Coyle PK. Disease-modifying agents in multiple sclerosis. Ann Indian Acad Neurol. 2009;12:273–82
22. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003;41:582–92
23. Kappos L, Gold R, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, et al. Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: the DEFINE study. Mult Scler. 2014;20:243–52
24. Centers for Disease Control and Prevention. Available from: http://www.cdc.gov/nchs/fastats/obesity-overweight.htm (accessed 2014 July 3) Obesity and overweight. Georgia: CDC; 2014
25. Trojano M, Pellegrini F, Paolicelli D, Fuiani A, Zimatore GB, Tortorella C, et al. Real-life impact of early interferon beta therapy in relapsing multiple sclerosis. Ann Neurol. 2009;66:513–20
26. Shirani A, Zhao Y, Karim ME, Evans C, Kingwell E, van der Kop ML, et al. Association between use of interferon beta and progression of disability in patients with relapsingremitting multiple sclerosis. JAMA. 2012;308:247–56
27. Cree BA, Kornyeyeva E, Goodin DS. Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. Ann Neurol. 2010;68:145–50
28. Ciccone A, Beretta S, Brusaferri F, Galea I, Protti A, Spreafico C. Corticosteroids for the long-term treatment in multiple sclerosis. Cochrane Database Syst Rev. 2008;1:CD006264
29. Menzin J, Caon C, Nichols C, White LA, Friedman M, Pill MW. Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis. J Manag Care Pharm. 2013;19:S24–S40
30. Taylor KL, Hadgkiss EJ, Jelinek GA, Weiland TJ, Pereira NG, Marck CH, et al. Lifestyle and demographic factors and medications associated with depression risk in an international sample of people with multiple sclerosis. BMC Psychiatry. 2014; 14:327
31. Sheng P, Hou L, Wang X, Wang X, Huang C, Yu M, et al. Efficacy of modafinil on fatigue and excessive daytime sleepiness associated with neurological disorders: a systematic review and meta-analysis. PLoS One. 2013;8:e81802
32. Weiland TJ, Jelinek GA, Marck CH, Hadgkiss EJ, van der Meer DM, Pereira NG, et al. Clinically significant fatigue: prevalence and associated factors in an international sample of adults with multiple sclerosis. PLoS One. 2015; 10(2):e0115541
33. Thelen JM, Lynch SG, Bruce AS, Hancock LM, Bruce JM. Polypharmacy in multiple sclerosis: relationship with fatigue, perceived cognition, and objective cognitive performance. J Psychosom Res. 2014;76:400–4
34. Zwibel HL, Smrtka J. Improving quality of life in multiple sclerosis: an unmet need. Am J Manag Care. 2011;17(Suppl 5):S139–45
35. Berger JR. Functional improvement and symptom management in multiple sclerosis: clinical efficacy of current therapies. Am J Manag Care. 2011;17(Suppl 5):S146–53
36. Johnson KP, Due DL. Benefits of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis. Expert Rev Pharmacoecon Outcomes Res. 2009;9:205–14
37. Ziemssen T, Bajenaru OA, Carra´ A, de Klippel N, de Sa´ JC, Edland A, et al. A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial. J Neurol. 2014;261(11):2101–11.